In the Utah Cancer Survivors Study, male thyroid cancer survivors had an almost 50% higher risk of developing cardiovascular disease than females.
A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.
The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer.
A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab–based therapy.
In the Italian RESORT trial, sorafenib did not affect recurrence-free survival in patients with mRCC following radical resection of metastases.
Making some changes to the gut microbiome may improve outcomes with immune checkpoint inhibitors in renal cell carcinoma.
Pembrolizumab represents a new standard first-line treatment option for PD-L1–expressing advanced/metastatic NSCLC, according to KEYNOTE-042 investigators.
In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.